New Tuberculosis Vaccine Candidate Developed: Improved Delivery Of Antigens By Current Vaccine BCG (Bacille Calmette-Gurin)

Scientists at the Max Planck Institute for Infection Biology, Berlin and at the University Clinics of Ulm have developed a putative vaccine candidate against Mycobacterium tuberculosis, the causative agent of tuberculosis. Their data have been published in the Proceedings of the National Academy of Sciences U.S.A. on April 28, 1998.

Although tuberculosis belongs to the "old" diseases, it still remains a significant global health problem. Tuberculosis is responsible for 3 million deaths annually - more than at any time-point before and more than any other infectious agent. Moreover, it has been estimated that half a billion people will suffer from tuberculosis by the year 2050. Already in 1927, a vaccine was developed which was termed bacille Calmette-Gurin (BCG) to honour the scientists who attenuated Mycobacterium bovis by more than 230 passages on bile glycerol agar. In many countries the only measure for tuberculosis control has been vaccination with BCG. General agreement exists that BCG can protect or at least ameliorate severe forms of tuberculosis in children. Yet, it seems to be of low or no protective value in adults.

M. tuberculosis belongs to the group of intracellular bacteria that replicate within the phagosomal vacuoles of resting macrophages and protection against tuberculosis depends on T cell-mediated immunity. Major histocompatiblity complex (MHC) class II-restricted CD4 T helper cells and MHC class I-restricted cytotoxic CD8 T cells are stimulated during M.tuberculosis infection, but the current BCG vaccine fails to prime CD8 T cells for tuberculosis prevention.

Over the last few years, Juergen Hess and Stefan H.E. Kaufmann from the Max Planck Institute for Infection Biology in Berlin and the University Clinics of Ulm developed recombinant ( r )- BCG strains which secrete pore-f

Contact: Juergen Hess

Page: 1 2

Related biology news :

1. Scientists Identify Molecular Target For Tuberculosis Drug Treatment
2. Scientists Unlock Mystery Behind Proteins That Keep Tuberculosis Bacteria Alive; Finding Leads To Research Into New Drug Treatments
3. Hope Clinic of Emory Vaccine Center receives CDC contract
4. Vaccines against foodborne disease on horizon
5. GenVec, U.S. NMRC, and PATHs Malaria Vaccine Initiative partner to expand malaria vaccine efforts
6. Vaccine technique shows potential against common form of lung cancer
7. Fighting fire with fire? Vaccine based on chimp virus shows promise against HIV
8. Emory Vaccine Research Center study identifies specific gene required for long-term immunity
9. Vaccine prevents stroke in rats
10. Vaccine puts blood-sucking ticks off their food
11. Vaccine protects against fatal West Nile complication

Post Your Comments:

(Date:4/12/2019)... ... 11, 2019 , ... Neal O’Farrell is one of the first generation of ... executive director of the consumer advocacy non-profit the Identity Theft Council as well as ... the Federal Communications Commission’s Cybersecurity Roundtable and is currently a fellow of the EP3 ...
(Date:4/9/2019)... ... April 09, 2019 , ... The McLeod Center for Cancer Treatment and ... rigorous and voluntary audit conducted by an independent, third-party panel of experts in radiation ... in the United States, McLeod is the only such cancer center in South Carolina. ...
(Date:4/4/2019)... ... April 02, 2019 , ... The live session ... into the connectivity between product risk management (ISO 14971) and the clinical risk ... process. , With increasing global regulation and reimbursement challenges faced by medical device ...
Breaking Biology News(10 mins):
(Date:3/19/2019)... ... March 19, 2019 , ... Konica Minolta Precision Medicine, Inc. ... of their inaugural Scientific Advisory Board. , Founded in late 2018, ... individual variability in genes, environment, and lifestyle to more accurately predict, detect, treat ...
(Date:3/18/2019)... ... March 18, 2019 , ... For more than 15 years, USDM ... allow life science companies to easily comply with FDA 21 CFR Part 11 and ... a managed service delivering end-to-end GxP compliance from vendor audit through ongoing validation maintenance, ...
(Date:3/14/2019)... ... March 14, 2019 , ... Open registration for the ... Full Spectrum of Case Management,” continues as CMSA makes plans to host the ... only case management industry conference serving the educational and networking needs of case ...
(Date:3/14/2019)... ... March 14, 2019 , ... ... standard solution for preclinical research organizations. It is a low code, GDPR/21 ... systems and facilities, innovative technology-driven automated data capture and seamless data and ...
Breaking Biology Technology:
Cached News: